UBS Maintains Neutral on Center, Lowers Price Target to $65
UBS maintains Center (NYSE:CSR) with a Neutral and lowers the price target from $68 to $65.
Stocks · News reference
Cantor Fitzgerald Reiterates Neutral on Center, Maintains $57 Price Target
Cantor Fitzgerald analyst Richard Anderson reiterates Center (NYSE:CSR) with a Neutral and maintains $57 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Piper Sandler Maintains Neutral on Center, Lowers Price Target to $56
Piper Sandler analyst Alexander Goldfarb maintains Center (NYSE:CSR) with a Neutral and lowers the price target from $58 to $56.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.
8-K filing — CENTERSPACE (CSR)
Filed: 2026-09-23 AccNo: 0001140361-26-037453 Size: 239 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits